# An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

Source: https://onco.cc/trials/nct07720284/  
OnCo record `nct07720284` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab and Enfortumab vedotin in bladder & urothelial cancer, run by AstraZeneca, now recruiting.

## Summary

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC is a phase 3 interventional study registered as NCT07720284 by AstraZeneca, with 915 participants planned, started 2026-07-16 and due to reach its primary completion in 2030-09-11. Interventions recorded: Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab and Enfortumab vedotin.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07720284
- Phase: 3
- Setting: A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma
- Sponsor: AstraZeneca
- Enrolled: 915

## Sources

- ClinicalTrials.gov NCT07720284: https://clinicaltrials.gov/study/NCT07720284

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Durvalumab](https://onco.cc/drugs/durvalumab/), [Enfortumab vedotin](https://onco.cc/drugs/enfortumab-vedotin/), [Nivolumab](https://onco.cc/drugs/nivolumab/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Rilvegostomig](https://onco.cc/drugs/rilvegostomig/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/), [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct07720284.json